Novavax Receives the US FDA’s Fast Track Designation for NVX-CoV2373 to Treat COVID-19

November 10, 2020 Auto Bot Clinical Trials, Fast Track Designation, Novavax, NVX-CoV2373, receives, Treat, US FDA’s 0

Shots:

  • The US FDA has granted FT designation to NVX-CoV2373 which is currently in late-phase clinical development. Novavax expects to initiate pivotal P-III study in the US & Mexico by the end of Nov’2020
  • The company’s ongoing P-lll trial in the UK to evaluate the efficacy, safety, and immunogenicity of NVX-CoV2373 is expected to be fully enrolled by the end of Nov. Depending on the overall COVID-19 attack rate, interim data in the UK trial is expected in Q1’21
  • NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant

Click here ­to­ read full press release/ article | Ref: Novavax | Image: Newsroom Keck Medicine of USC

The post Novavax Receives the US FDA’s Fast Track Designation for NVX-CoV2373 to Treat COVID-19 first appeared on PharmaShots.